2025
Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil
Verruck J, Puga M, de Oliveira R, da Silva P, Charu V, Hedlin H, Lu D, Zhang A, Ritter V, Shaw B, Rosser J, Seidman J, Carter A, Qamar F, Luby S, Garret D, Croda J. Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil. BMJ Public Health 2025, 3: e002331. PMID: 40620571, PMCID: PMC12228459, DOI: 10.1136/bmjph-2024-002331.Peer-Reviewed Original ResearchDose of BNT162b2Fractionated dosesFollow-up visitIgG antibody levelsFollow-upFull doseAntibody levelsAntibody titresDays of follow-upDays post-booster vaccinationBaseline antibody titresClinically protective levelsFollow-up periodHealthy adultsDose of COVID-19 vaccineDays post-boosterBooster dose of BNT162b2Post-booster vaccinationFull-doseBooster doseIgG levelsAZD1222Post-boosterBNT162b2High antibody titresImmunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil
Puga M, de Oliveira R, da Silva P, Charu V, Hedlin H, Lu D, Zhang A, Shaw B, Rosser J, Seidman J, Carter A, Qamar F, Luby S, Garrett D, Croda J. Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil. The Lancet Regional Health - Americas 2025, 44: 101031. PMID: 40083966, PMCID: PMC11904515, DOI: 10.1016/j.lana.2025.101031.Peer-Reviewed Original ResearchDose of BNT162b2Fractionated dosesNon-inferiorityNon-inferiority thresholdSeroresponse ratesDouble-blindBooster vaccinationAdverse eventsSystemic adverse eventsPhase IV clinical trialBaseline antibody levelsIV clinical trialDose of COVID-19 vaccineDose of vaccineNon-inferiority studyReduced side effectsAdministering booster vaccinationResource-limited settingsBinding IgG antibodiesImmunocompetent adultsStudy vaccineDose boosterTreatment armsParallel-groupBooster dose
2021
Exosomes of MSCs target M2-type Macrophages to promote TGF-β-Dependent Microvascular Stabilization and Functional Recovery in Spinal Cord Injury
Askenase P. Exosomes of MSCs target M2-type Macrophages to promote TGF-β-Dependent Microvascular Stabilization and Functional Recovery in Spinal Cord Injury. The Journal Of Immunology 2021, 206: 95.06-95.06. DOI: 10.4049/jimmunol.206.supp.95.06.Peer-Reviewed Original ResearchMesenchymal stromal cellsSpinal cord injuryM2-type macrophagesFractionated dosesTGF-bExpression of TGF-BMesenchymal stromal cell infusionInfusion of mesenchymal stromal cellsSevere contusion spinal cord injuryMSC-ExosTherapeutic effectInfused mesenchymal stromal cellsInjury siteBlood-spinal cord barrierTGF-B pathwayContusive spinal cord injuryCord injuryIntravenous (IVFunctional neurological recoverySprague Dawley ratsTight junction proteinsYoung Sprague Dawley ratsSingle doseDawley ratsNeurological recovery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply